Cargando…

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT

BACKGROUND: An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. OBJECTIVES: The purpose of this study was to clarify this unexpected finding in a larger sample size of patients stabilized after ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giugliano, Robert P., Gencer, Baris, Wiviott, Stephen D., Park, Jeong-Gun, Fuchs, Charles S., Goessling, Wolfram, Musliner, Thomas A., Tershakovec, Andrew M., Blazing, Michael A., Califf, Robert, Cannon, Christopher P., Braunwald, Eugene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352126/ https://www.ncbi.nlm.nih.gov/pubmed/34396246 http://dx.doi.org/10.1016/j.jaccao.2020.07.008

Ejemplares similares

Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT
por: Shah, Nishant P., et al.
Publicado: (2023)

Establishment of normal reference range for thromboelastography based on 17,708 cases in Beijing, China
por: Wei, Chao, et al.
Publicado: (2022)

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
por: Kato, Eri Toda, et al.
Publicado: (2017)

Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long‐Term Follow‐Up After Acute Coronary Syndromes
por: Fanaroff, Alexander C., et al.
Publicado: (2017)

Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT
por: Fordyce, Christopher B., et al.
Publicado: (2022)

Management of LDL‐cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers
por: Gencer, Baris, et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia
por: Saito, Itori, et al.
Publicado: (2015)

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
por: Kato, Eri Toda, et al.
Publicado: (2022)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2016)

Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
por: Abramson, Beth L, et al.
Publicado: (2011)

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk
por: Rosen, Jeffrey B., et al.
Publicado: (2015)

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
por: Constance, Christian, et al.
Publicado: (2014)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

708 Serratia infections in burn care
por: Rogers, Alan D, et al.
Publicado: (2022)

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
por: Guyton, John R., et al.
Publicado: (2012)

Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin in Patients With Type 2 Diabetes and Hypercholesterolemia
por: Goldberg, Ronald B., et al.
Publicado: (2010)

Synergistic effects of miR-708-5p and miR-708-3p accelerate the progression of osteoporosis
por: Wang, Ruran, et al.
Publicado: (2020)

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
por: Le, Ngoc‐Anh, et al.
Publicado: (2015)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease
por: Guthrie, Robert
Publicado: (2010)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
por: Bays, Harold E., et al.
Publicado: (2021)

SAT-708 The Effect of Soybean Isoflavones in Developing Cerebellum
por: Ariyani, Winda, et al.
Publicado: (2020)

Ezetimibe therapy: mechanism of action and clinical update
por: Phan, Binh An P, et al.
Publicado: (2012)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Synthesis and Modeling of Ezetimibe Analogues
por: Salgado, Mateo M., et al.
Publicado: (2021)

Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Remediation of ABCG5-Linked Macrothrombocytopenia With Ezetimibe Therapy
por: Deng, Libin, et al.
Publicado: (2021)

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years
por: Ben-Yehuda, Ori, et al.
Publicado: (2011)

Correction to Lancet Child Adolesc Health 2021; 5: 708–18
Publicado: (2021)

miR-708-5p Regulates Myoblast Proliferation and Differentiation
por: Xu, Xueli, et al.
Publicado: (2022)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease
por: Tadiboyina, Venu T, et al.
Publicado: (2005)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
por: Xu, Haiyan, et al.
Publicado: (2016)

Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study
por: Correia, Luis C. L.
Publicado: (2016)

Impact on urinary oxalate levels with use of ezetimibe
por: Trautman, Christopher L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k9vq6mrjl3talv06ktouggrjic